{
  "meta": {
    "title": "Aki_Vs_Ckd",
    "url": "https://brainandscalpel.vercel.app/aki-vs-ckd-fb9f9a74.html",
    "scrapedAt": "2025-11-30T11:19:21.665Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Start oral cyclophosphamide for 8-12 weeks</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Add mycophenolate mofetil to corticosteroid therapy</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Initiate calcineurin inhibitor therapy (e.g., tacrolimus or cyclosporine)</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Administer rituximab immediately</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-year-old boy with nephrotic syndrome has been on high-dose corticosteroids for 4 weeks. Despite adherence to therapy, he continues to have generalised oedema and persistent proteinuria. His urine protein: creatinine ratio remains >2, and he has not achieved remission. A kidney biopsy is planned. Which of the following is the next best step in the management of this patient?</span></p>",
      "unique_key": "DT1325163",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325163,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The child has not achieved remission after 4 weeks of corticosteroid therapy, which meets the definition of <strong>steroid-resistant nephrotic syndrome (SRNS).</strong> In SRNS, the first-line steroid-sparing agents recommended are<strong> calcineurin inhibitors like tacrolimus or cyclosporine.</strong></p>\r\n<p><strong>Management of Steroid-Resistant / Frequent / Steroid-Dependent NS:</strong></p>\r\n<p><strong>1. Cyclophosphamide: (Option A)</strong></p>\r\n<ul>\r\n<li><strong>Indications:</strong> Frequent relapsers and steroid-dependent cases.</li>\r\n<li><strong>Dose:</strong> 2 mg/kg orally once daily for <strong>8-12 weeks</strong>.</li>\r\n<li><strong>Often given with:</strong> Alternate-day prednisone.</li>\r\n<li><strong>Monitoring:</strong> Weekly <strong>WBC count</strong>; withhold if &lt;5,000/mm&sup3;.</li>\r\n<li><strong>Cumulative dose risk:</strong> &gt;250 mg/kg &rarr; risk of <strong>oligospermia/azoospermia</strong>.</li>\r\n<li><strong>Side effects:</strong> Neutropenia, hemorrhagic cystitis, alopecia, sterility, and malignancy risk.</li>\r\n</ul>\r\n<p><strong>2. Calcineurin Inhibitors (Cyclosporine, Tacrolimus): (Option C)</strong></p>\r\n<ul>\r\n<li><strong>Indication:</strong> First-line for <strong>SRNS</strong>.</li>\r\n<li><strong>Side effects:</strong> Hypertension, nephrotoxicity, hirsutism, and gingival hyperplasia.</li>\r\n</ul>\r\n<p><strong>3. Mycophenolate Mofetil: (Option B)</strong></p>\r\n<ul>\r\n<li><strong>Use:</strong> Maintains remission in <strong>frequent relapsers</strong> or <strong>steroid-dependent</strong></li>\r\n</ul>\r\n<p><strong>4. Levamisole:</strong></p>\r\n<ul>\r\n<li><strong>Use:</strong> Reduces relapse risk (compared to prednisone).</li>\r\n<li><strong>Note:</strong> Not available in the United States.</li>\r\n</ul>\r\n<p><strong>5. Rituximab: (Option D)</strong></p>\r\n<ul>\r\n<li><strong>Type:</strong> Anti-CD20 monoclonal antibody.</li>\r\n<li><strong>Effectiveness:</strong> Maintains remission and reduces relapses in <strong>steroid-dependent/resistant</strong></li>\r\n<li><strong>Response Rate:</strong> Up to <strong>80% drug-free remission</strong> at 1 year in steroid-dependent cases.</li>\r\n<li><strong>Less effective</strong> in <strong>multidrug-resistant</strong> cases already on steroids + calcineurin inhibitors.</li>\r\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Loss of charge selectivity in the glomerular basement membrane</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Immune complex deposition in the mesangium</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Injury to the podocyte slit diaphragm</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased mesangial matrix expansion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 5-year-old boy presents with generalised oedema and frothy urine. Laboratory studies reveal hypoalbuminemia and massive proteinuria. Renal biopsy shows no abnormalities on light microscopy, but electron microscopy reveals podocyte foot process effacement. Which of the following best explains the pathophysiology of this child's condition?</span></p>",
      "unique_key": "DT1325164",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325164,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical scenario points toward a diagnosis of <strong>nephrotic syndrome</strong>, as evidenced by generalised oedema, frothy urine, hypoalbuminemia, and massive proteinuria. This occurs due to <strong>podocyte injury</strong> leading to <strong>disruption of the slit diaphragm</strong>, which increases glomerular permeability and allows protein to leak into the urine.</p>\r\n<p><strong>Pathogenesis of Nephrotic Syndrome:</strong></p>\r\n<p><strong>Role of the Podocyte:</strong></p>\r\n<ul>\r\n<li><strong>Primary abnormality</strong>: Increased glomerular capillary wall permeability &rarr; massive proteinuria &amp; hypoalbuminemia.</li>\r\n<li><strong>Podocyte location</strong>: Outside the glomerular capillary loop; has foot processes that interdigitate with adjacent podocytes.</li>\r\n<li><strong>Functions of podocyte</strong>:\r\n<ul>\r\n<li>Structural support for the capillary loop.</li>\r\n<li>Part of the glomerular filtration barrier.</li>\r\n<li>Synthesises and repairs the glomerular basement membrane.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Genetic causes of podocyte injury</strong>:\r\n<ul>\r\n<li>Mutations in podocyte genes (e.g., NPHS1, NPHS2, WT1) &rarr; nephrotic-range proteinuria.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Mechanisms of podocyte injury</strong>:\r\n<ul>\r\n<li>Foot process effacement.</li>\r\n<li>Decreased functional podocyte number.</li>\r\n<li>Disruption of the slit diaphragm &rarr; protein leak into urine.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Role of the Immune System:</strong></p>\r\n<ul>\r\n<li><strong>Minimal Change Nephrotic Syndrome (MCNS)</strong>:\r\n<ul>\r\n<li>Often follows <strong>viral infections</strong> or <strong>allergen exposure</strong>.</li>\r\n<li>Associated with <strong>Hodgkin's lymphoma</strong> and <strong>T-cell lymphoma</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Response to immunosuppressants</strong> (e.g., steroids, cyclosporine) suggests immune involvement.</li>\r\n<li><strong>Focal Segmental Glomerulosclerosis (FSGS)</strong>:\r\n<ul>\r\n<li>~30% recurrence post-transplantation &rarr; implies role of circulating <strong>permeability factor</strong>.</li>\r\n<li>Sera from FSGS patients &rarr; increased albumin permeability in rat glomeruli.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Autoantibodies</strong>:\r\n<ul>\r\n<li>Circulating <strong>nephrin autoantibodies</strong> found in some MCNS patients &rarr; immune-mediated injury.</li>\r\n</ul>\r\n</li>\r\n</ul>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemodialysis</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Peritoneal Dialysis</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemofiltration</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Peritoneal Lavage</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which procedure is being performed in this 2-year-old child who presented with low urine output and serum potassium of 7.2 despite medical management?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403197d70d018-cbd7-481b-b97f-5effb8e0804f.png\"></span></p>",
      "unique_key": "DT1230362",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230362,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Peritoneal Dialysis (PD):</strong></p>\r\n<ul>\r\n<li><strong>Most commonly used in neonates and infants</strong> with AKI.</li>\r\n<li>Can also be used in <strong>children and adolescents of all ages</strong>.</li>\r\n<li>Involves infusion of <strong>hyperosmolar dialysate</strong> into the <strong>peritoneal cavity</strong> via a <strong>PD catheter</strong> (surgically or percutaneously placed).</li>\r\n<li>The fluid is allowed to <strong>dwell for 45-60 minutes</strong>, then <strong>drained by gravity</strong>, either:\r\n<ul>\r\n<li><strong>Manually</strong>, or</li>\r\n<li>With a <strong>machine-driven cycling system</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Cycles repeated for 8-24 hours per day</strong> based on fluid and electrolyte needs.</li>\r\n<li><strong>Anticoagulation is not required</strong>.</li>\r\n<li><strong>Contraindicated in patients with significant abdominal pathology</strong>.</li>\r\n</ul>\r\n<p><strong>Intermittent Hemodialysis (IHD): (Option A)</strong></p>\r\n<ul>\r\n<li>Best suited for patients with <strong>relatively stable hemodynamic status</strong>.</li>\r\n<li>A <strong>highly efficient</strong> process for both <strong>fluid and electrolyte removal</strong>.</li>\r\n<li>Performed via a <strong>pump-driven extracorporeal circuit</strong> using a <strong>large central venous catheter</strong>.</li>\r\n<li>Typical session duration: <strong>3-4 hours</strong>.</li>\r\n<li>Frequency: <strong>3-7 times per week</strong>, depending on patient's fluid and electrolyte needs.</li>\r\n</ul>\r\n<p><strong>Comparison of Peritoneal Dialysis (PD) and Intermittent Hemodialysis (IHD):</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090644b6d1ee-80ea-4904-b99e-9d03704ff87d.png\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090644b6d1ee-80ea-4904-G553t-9d03704ff87d.png\">\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Hemofiltration (Option C):</strong> Used primarily in critical care settings for continuous therapy, not the first-line option in stable pediatric patients.</p>\r\n<p><strong>Peritoneal Lavage (Option D):</strong> Used for abdominal conditions like hypothermia or peritonitis, not for managing renal failure or hyperkalemia.</p>",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate start of growth hormone therapy</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Correction of metabolic acidosis and hyponatremia if present</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Planning limb-lengthening surgery</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Planning renal transplantation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 11 years diagnosed CKD secondary to renal hypoplasia. Upon reviewing the history, you found that her height is significantly below the third percentile for her age. What is the most appropriate 1st step in the management of her growth retardation?</span></p>",
      "unique_key": "DT1230343",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230343,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This is a very useful concept-based clinical scenario, put in this Q bank to highlight a very important message for students. Read the explanation carefully.</p>\n<ul>\n<li><strong>For children with CKD</strong>, medical complications include growth impairment. The cause of <strong>growth impairment is multifactorial and includes malnutrition, metabolic acidosis, electrolyte imbalances</strong>(such as hyponatremia), and <strong>renal osteodystrophy.</strong></li>\n<li>A key factor is that <strong>CKD </strong>results in an apparent<strong>growth hormone-resistant state</strong>, with elevated growth hormone levels but <strong>decreased insulin-like growth factor 1 levels </strong>and abnormalities of insulin-like growth factor-binding proteins.</li>\n<li>Correction of <strong>any metabolic acidosis and hyponatremia</strong> is the initial step in the management of <strong>growth impairment.</strong></li>\n<li>In addition, if evidence of malnutrition is present, the addition of <strong>protein powders or supplemental renal formulas </strong>should be considered to increase caloric density.</li>\n<li><strong>Children with CKD who remain less than -2 SD for height </strong>despite optimal medical support (adequate caloric intake and effective treatment of renal osteodystrophy, anaemia, and metabolic acidosis) may benefit from t<strong>reatment with recombinant human growth hormone (rHuGH).</strong></li>\n<li><strong>Early recognition and management of malnutrition, mineral bone disease, metabolic acidosis </strong>and electrolyte disturbances take precedence over <strong>therapy with growth hormone.</strong></li>\n<li>A <strong>gastrostomy tube </strong>can be considered in an infant or young child if they are unlikely to take in the required volume and calories by mouth.</li>\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Fall in 1, 25-DHCC levels</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Rise in FGF-23 levels</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Fall in FGF-23 levels</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Rise in PTH levels</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An early marker of Mineral and Bone Disorder in CKD patients is?</span></p>",
      "unique_key": "DT1230382",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230382,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Chronic kidney disease </strong>is characterised by <strong>systemic disorders of calcium, phosphorus, PTH, and vitamin D metabolism </strong>that can not only lead to <strong>bone disorders (renal osteodystrophy) but also vascular and soft tissue calcification. </strong>Previously called<strong> Renal Osteodystrophy, </strong>it is now called as CKD-MBD.</p>\n<ul>\n<li>Efforts have focused on the role of the <strong>hormone fibroblast growth factor 23 (FGF23)</strong>and its cofactor, Klotho, in <strong>CKD-MBD.</strong></li>\n<li>An <strong>elevated FGF23 r</strong>esults in<strong><strong> increased</strong> urinary phosphate excretion </strong>and<strong> suppression of 1-&alpha;hydroxylase activity</strong>, leading to r<strong>educed 1,25-dihydroxycholecalciferol (1,25(OH)2D) values and increased PTH secretion.</strong></li>\n<li><strong>Elevated FGF23 </strong>is th<strong>e first sign of altered osteocyte function in pediatric and adult CKD,</strong> is seen as <strong>early as CKD stage 2 (GFR 60-90 mL/min/1.73 m2</strong>), and occurs <strong>despite normal calcium, phosphorus, PTH, and 1,25OH2 D levels.</strong></li>\n</ul>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Phosphorus</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Protein</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 7-year-old boy with renal dysplasia and chronic kidney disease is being followed in the clinic. He has a history of polyuria and increased thirst. His current medications include sodium bicarbonate, ferrous sulfate, calcium carbonate, and calcitriol. His weight and height are both below the 5th percentile. Of the following, the MOST appropriate dietary restriction for this child is:</span></p>",
      "unique_key": "DT1230394",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230394,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Dietary restriction of phosphorus</strong>in<strong> chronic kidney disease </strong>controls <strong>hyperphosphatemia and secondary hyperparathyroidism.</strong></li>\n<li>CKD patients of all ages should typically follow a<strong>low-phosphorus diet to maintain age-appropriate serum phosphorus values.</strong></li>\n<li>Some patients are also often given phosphate binders with meals as a part of the management and prevention of <strong>CKD-MBD.</strong></li>\n<li>Protein restriction is not recommended in infants and children who have chronic kidney disease.</li>\n</ul>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Stage 1</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Stage 2</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Stage 3</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Stage 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-year-old child has a weight of 12 kg. His urine output is 0.4 ml/kg/hr over the last 12 hours, and serum creatinine has doubled over the baseline. What is the stage of AKI by KDIGO Criteria?</span></p>",
      "unique_key": "DT1230347",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230347,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>As the child has a <strong>urine output of 0.4ml/kg/hr</strong> for the <strong>last 12 hrs,</strong> it is staged as <strong>Stage 2 of AKI</strong> based on KDIGO staging.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202410039d011a73-034a-40ba-a155-976b52f08fab.jpg\">",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">The Injury stage is defined by a 50% decrease in estimated creatinine clearance or urine output <0.5 mL/kg/h for 16 hours.</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">The Failure stage includes either a 75% drop in eCCI or an eCCI <35 mL/min/1.73 m<sup>2</sup></span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">The Loss stage is defined as persistent renal dysfunction lasting more than 1 week.</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">End-stage renal disease is diagnosed when renal failure persists for more than 3 months.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding the pRIFLE criteria for acute kidney injury in children is incorrect?</span></p>",
      "unique_key": "DT1230354",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230354,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>\"Loss\" stage is defined as <strong>persistent kidney failure lasting more than 4 weeks</strong>, not 1 week.</p>\r\n<p><strong>RIFLE Criteria</strong> are used in AKI. In children, we use <strong>pediatric-RIFLE criteria,</strong> also written as pRIFLE Criteria.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20241003f64c4e12-365a-420f-8abd-e96ddbf3500e.jpg\">",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">33 ml/min/1.73 m&#178; BSA</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">40 ml/min/1.73 m&#178; BSA</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">55 ml/min/1.73 m&#178; BSA</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">80 ml/min/1.73 m&#178; BSA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 4-year-old male child with a body weight of 15 kg and height of 100 cm is admitted with renal failure. His blood urea was 100 mg/dl, and serum creatinine was 1 mg/dl. What is the closest calculated eGFR in the patient?</span></p>",
      "unique_key": "DT1230289",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The<strong> modified Schwartz formula</strong> is often used to measure the estimated GFR in a child. The formula is as follows</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024100307cbaf0c-66cf-4bb5-937e-fa33dfe3864d.jpg\">\n<p>Please note <strong>that blood urea is not used to determine GFR.</strong> Applying the values given in the question, the closest answer here will be option B.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4, 5</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 4, 5, 6</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4, 6</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 4, 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements correctly differentiates prerenal AKI from intrinsic renal AKI?<br>1. Urine specific gravity is typically >1.020 in prerenal AKI.<br>2. Urine osmolality is lower in prerenal AKI compared to intrinsic AKI.<br>3. Urine sodium concentration is usually <20 mEq/L in prerenal AKI.<br>4. Fractional excretion of sodium (FeNa) is >2% in intrinsic renal AKI.<br>5. Urine osmolality >350 mOsm/kg is suggestive of intrinsic AKI.<br>6. Urine-to-plasma creatinine ratio is typically >40:1 in prerenal AKI.</span></p>",
      "unique_key": "DT1230279",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230279,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The correct answers are <strong>statements 1, 3, 4 and 6.</strong></p>\n<p><strong>Prerenal Acute Kidney Injury (AKI):</strong></p>\n<ul>\n<li>Caused by <strong>diminished effective circulating arterial volume</strong> &rarr; leads to <strong>inadequate kidney perfusion</strong> and <strong>decreased GFR</strong>.</li>\n<li><strong>No structural kidney damage</strong></li>\n<li><strong>Common causes:</strong>\n<ul>\n<li>Dehydration</li>\n<li>Sepsis</li>\n<li>Hemorrhage</li>\n<li>Severe hypoalbuminemia</li>\n<li>Cardiac failure</li>\n</ul>\n</li>\n</ul>\n<p><strong>Intrinsic Renal AKI:</strong></p>\n<ul>\n<li>Involves <strong>actual parenchymal kidney damage</strong>.</li>\n<li>Often follows <strong>sustained ischemia or nephrotoxic injury</strong>.</li>\n<li>Common in patients with:\n<ul>\n<li>Cardiac, oncologic, urologic, renal, or genetic disorders</li>\n<li>Prematurity</li>\n</ul>\n</li>\n<li><strong>Urinary findings suggestive of intrinsic AKI:</strong>\n<ul>\n<li>Hematuria</li>\n<li>Proteinuria</li>\n<li>Red blood cell casts</li>\n<li>Granular casts</li>\n</ul>\n</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a0f7960b-fd45-4014-9a68-52e9061e9cee.png\">",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Psychotherapy</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Bladder training with reward for daytime control</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Pharmacological therapy with imipramine</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Bell and pad-based classical conditioning</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 7-year-old boy has ha istory of regular bed-wetting, twice a week, for many years. With thorough investigations, an organic cause was ruled out. The boy was mentally distressed due to bed-wetting. What should be the initial therapy?</span></p>",
      "unique_key": "DT1230302",
      "question_audio": null,
      "question_video": null,
      "map_id": 1230302,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The child is suffering from <strong>nocturnal enuresis</strong><strong>, and the 1st line therapy</strong> is always non-pharmacological, comprising motivation &amp; use of alarm devices.</p>\n<p><strong>Management of </strong><strong>Nocturnal Enuresis:</strong></p>\n<ul>\n<li><strong>Active treatment </strong>started after<strong> ruling out organic causes </strong>and<strong> beyond 6 years of age.</strong></li>\n<li>Fluid restriction in the evening is advised for most children</li>\n<li><strong>1st line therapy</strong> is always <strong>non-pharmacological</strong>, comprising motivation &amp; use of alarm devices.</li>\n<li><strong>Motivational therapy </strong>alone is successful in only 25% patients, using rewards for dry nights. However, bladder training exercises are not useful.</li>\n<li>Another<strong>1st line therapy is </strong><strong>the use of alarms, </strong>also known <strong>as bell and pad-based classical conditioning.</strong> These special devices are<strong> useful 7 years of age</strong> onwards and are effective in 2/3rd. Whenever the child gets wet, the sensors in the device make the alarm ring, waking the child. This slowly conditions the child to awaken when the bladder is full and void urine.</li>\n<li>The <strong>combination</strong>of motivational and alarm therapy is successful in up to 60-70% of patients.</li>\n<li>Pharmacotherapy using<strong>oral desmopressin</strong> is used if <strong>1st line measures fail.</strong> But have a risk of relapse and side effects.</li>\n</ul>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}